Chasity D Andrews
Overview
Explore the profile of Chasity D Andrews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andrews C, Huang Y, Ho D, Liberatore R
Emerg Microbes Infect
. 2020 Jun;
9(1):1523-1533.
PMID: 32579067
With increasing frequency, humans are facing outbreaks of emerging infectious diseases (EIDs) with the potential to cause significant morbidity and mortality. In the most extreme instances, such outbreaks can become...
2.
Markowitz M, Gettie A, St Bernard L, Andrews C, Mohri H, Horowitz A, et al.
J Infect Dis
. 2019 Jun;
221(9):1398-1406.
PMID: 31175822
Background: MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine [EFdA]) is a novel reverse transcriptase-translocation inhibitor. Methods: We assessed MK-8591 as preexposure prophylaxis in the rhesus macaque model of intrarectal challenge with simian/human immunodeficiency virus (SHIV)....
3.
Andrews C, Luo Y, Sun M, Yu J, Goff A, Glass P, et al.
Mol Ther Methods Clin Dev
. 2017 Oct;
7:74-82.
PMID: 29034261
Monoclonal antibodies (mAbs) have wide clinical utility, but global access is limited by high costs and impracticalities associated with repeated passive administration. Here, we describe an optimized electroporation-based DNA gene...
4.
Andrews C, St Bernard L, Poon A, Mohri H, Gettie N, Spreen W, et al.
AIDS
. 2016 Dec;
31(4):461-467.
PMID: 27902508
Objective: We evaluated the effectiveness of cabotegravir (CAB; GSK1265744 or GSK744) long acting as preexposure prophylaxis (PrEP) against intravenous simian immunodeficiency virus (SIV) challenge in a model that mimics blood...
5.
Song R, Pace C, Seaman M, Fang Q, Sun M, Andrews C, et al.
J Acquir Immune Defic Syndr
. 2016 Oct;
73(4):365-373.
PMID: 27792681
Background: Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly...
6.
Huang Y, Yu J, Lanzi A, Yao X, Andrews C, Tsai L, et al.
Cell
. 2016 Jun;
165(7):1621-1631.
PMID: 27315479
While the search for an efficacious HIV-1 vaccine remains elusive, emergence of a new generation of virus-neutralizing monoclonal antibodies (mAbs) has re-ignited the field of passive immunization for HIV-1 prevention....
7.
Li X, Kawamura A, Andrews C, Miller J, Wu D, Tsao T, et al.
J Immunol
. 2015 Aug;
195(6):2710-21.
PMID: 26254338
A CD1d-binding glycolipid, α-Galactosylceramide (αGalCer), activates invariant NK T cells and acts as an adjuvant. We previously identified a fluorinated phenyl ring-modified αGalCer analog, 7DW8-5, displaying nearly 100-fold stronger CD1d...
8.
Andrews C, Heneine W
Curr Opin HIV AIDS
. 2015 Jun;
10(4):258-63.
PMID: 26049951
Purpose Of Review: Preexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens...
9.
Andrews C, Yueh Y, Spreen W, St Bernard L, Boente-Carrera M, Rodriguez K, et al.
Sci Transl Med
. 2015 Jan;
7(270):270ra4.
PMID: 25589630
Long-acting GSK1265744 (GSK744 LA) is a strand transfer inhibitor of the HIV/SIV (simian immunodeficiency virus) integrase and was shown to be an effective preexposure prophylaxis (PrEP) agent in a low-dose...
10.
Andrews C, Spreen W, Mohri H, Moss L, Ford S, Gettie A, et al.
Science
. 2014 Mar;
343(6175):1151-4.
PMID: 24594934
GSK1265744 (GSK744) is an integrase strand-transfer inhibitor that has been formulated as a long-acting (LA) injectable suitable for monthly to quarterly clinical administration. GSK744 LA was administered at two time...